Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Liu D Qian HF Dynamic

    2020-08-12


    [3] Liu D, Qian HF. Dynamic contrast-enhanced magnetic resonance imaging permeability parameters monitor the early response to bevacizumab plus chemotherapy in colorectal cancer patients with liver metastases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2018;40(2):256.
    [4] Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Int J Gynecol Cancer 2017;75(1):284–98.
    [5] Telli ML, Audeh W, Jensen KC, Bose S, Timms K, Gutin A, et al. Abstract P5-06-01: homologous recombination deficiency (HRD) score predicts response to stan-dard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat 2017;75(Suppl.
    [6] Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, et al. Impact of sarcopenia on outcome in patients with esophageal resection fol-lowing neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol 2017;43(2):478–84.
    [7] Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Nakamura Y, et al. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surg Today 2017;47(1):65–73.
    [9] Ryu JM, Lee SK, Kim JY, Yu J, Kim SW, Lee JE, et al. Predictive factors for nonsentinel SCR-7 node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: nomogram for predicting nonsentinel lymph node metastasis. Clin Breast Cancer 2017;27(Suppl. (6)). S1526820917301453.
    [10] Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, et al. Tumor response to neoad-juvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial. Cancer 2017;123(9):1643–52.
    [11] Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, et al. Early results of a randomized two-by-two factorial phase II trial compar-ing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol 2017;28(8).
    Ethical approval
    Not required.
    Please cite this article in press as: Yang C, Zhao H. Application of dynamic magnetic resonance imaging information technology in adjuvant chemotherapy for breast cancer. J Infect Public Health (2019), https://doi.org/10.1016/j.jiph.2019.06.020
    Contents lists available at ScienceDirect
    International Immunopharmacology
    journal homepage: www.elsevier.com/locate/intimp
    Application of highly efficient and lowly toxic bufadienolides screened from T toad skin in lymphatic chemotherapy for colorectal cancer through a lymphatic metastatic model
    Changzheng Hea,1, Zhenyu Zoub,1, Shaoyou Xiaa,1, Xiaowei Xinga,1, Shidong Hua, Zilong Huc, Yuxuan Lia, Songyan Lia, Hongliang Zhanga, Yu Yanga, Yichen Liua, Xiaolei Xua, Boyan Liua, Yufeng Wangd, Yingxin Xue, , Xiaohui Dua,
    a Department of General Surgery, Chinese General Hospital of People's Liberation Army, Beijing 100853, PR China
    b Department of Hernia and Abdominal Wall Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, PR China
    c Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, PR China
    d Department of Patient Admission Management, Chinese General Hospital of People's Liberation Army, Beijing 100853, PR China
    e Institute of General Surgery, Chinese General Hospital of People's Liberation Army, Beijing 100853, PR China
    Keywords:
    Bufadienolides
    Colorectal cancer
    Emulsion
    Lymph node metastasis
    Lymphatic chemotherapy 
    Background: Lymph node metastasis (LNM) remains a major obstacle to treat colorectal cancer (CRC). Increasing evidences have suggested that bufadienolides contain several fractions displaying antitumor activity and may be applied in lymphatic chemotherapy. However, effects of the highly efficient and lowly toxic (HELT) bufadie-nolides on CRC in lymphatic chemotherapy have not been reported.
    Methods: Adenosine triphosphate tumor chemosensitivity assays (ATP-TCA) was performed to detect the in-hibition rate (IR) of fractions of bufadienolides to cytokine-induced killer (CIK) cells and tumor cells. HELT fraction-loaded emulsions of different concentrations were prepared. Nude mouse bearing HCT116 tumors in footpad received high-dose emulsion (HD-E), middle-dose emulsion (MD-E), low-dose emulsion (LD-E), control emulsion (CE), Cinobufacini Injection (CI), or normal saline (NS), respectively. Hematoxylin and eosin (H&E) staining, Flow Cytometry (FCM), enzyme-linked immune sorbent assay (ELISA) and hematological examination were applied to evaluate therapeutic effects and potential toxicity.